Research on real-world study of tafluprost in glaucoma and ocular hypertension
10.3760/cma.j.cn115989-20210418-00257
- VernacularTitle:他氟前列素治疗青光眼和高眼压症的真实世界研究
- Author:
Yue ZHANG
1
;
Yunxiao SUN
;
Ningli WANG
Author Information
1. 首都医科大学附属北京同仁医院 北京同仁眼科中心 北京市眼科研究所 眼科学与视觉科学北京市重点实验室 100005
- Keywords:
Glaucoma;
Ocular hypertension;
Tafluprost;
Real-world study
- From:
Chinese Journal of Experimental Ophthalmology
2021;39(10):910-914
- CountryChina
- Language:Chinese
-
Abstract:
Medication treatment is the most common measure for lowering intraocular pressure in glaucoma, and prostaglandin analogues have been unanimously recommended as the first choice for the treatment of glaucoma in multiple guidelines or consensus.Real-world studies (RWS) are observational studies in which diverse data are obtained in clinical environment, community or home settings to evaluate the real impact of some treatment on patients’ health.RWS have shown that tafluprost has a good effect on lowering intraocular pressure in patients with primary open angle glaucoma, ocular hypertension, normal tension glaucoma and other types of glaucoma, and it has mild ocular adverse effects in monotherapy for treatment-naive patients, alternative therapy and combination therapy.However, there are limiting factors for RWS such as the absence of the control group, and further studies are needed to evaluate the drug efficacy.In this article, the RWS of patients with different types of glaucoma and high intraocular pressure treated by tafluprost and the efficacy of tafluprost under different treatment modes as well as the safety of tafluprost and medication compliance in RWS were reviewed, so as to provide certain guidance for the practical clinical application of tafluprost.
